Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16α-18F-fluoro-17β-estradiol PET
Open Access
- 1 January 2009
- journal article
- review article
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 2 (1) , 7
Abstract
The most frequently used molecular imaging technique is currently 18F-deoxy-glucose (FDG) positron emission tomography (PET). FDG-PET holds promise in the evaluation of recurrent or residual ovarian cancer when CA125 levels are rising and conventional imaging, such as ultrasound, CT, or MRI, is inconclusive or negative. Recently, integrated PET/CT, in which a full-ring-detector clinical PET scanner and a multidetector helical CT scanner are combined, has enabled the acquisition of both metabolic and anatomic imaging data using one device in a single diagnostic session. This can also provide precise anatomic localization of suspicious areas of increased FDG uptake and rule out false-positive PET findings. FDG-PET/CT is an accurate modality for assessing primary and recurrent ovarian cancer and may affect management. FDG-PET/CT may provide benefits for detection of recurrent of ovarian cancer and improve surgical planning. And FDG-PET has been shown to predict response to neoadjuvant chemotherapy and survival in advanced ovarian cancer. This review focuses on the role of FDG-PET and FDG-PET/CT in the management of patients with ovarian cancer. Recently, we have evaluated 16α-18F-fluoro-17β-estradiol (FES)-PET, which detects estrogen receptors. In a preliminary study we reported that FES-PET provides information useful for assessing ER status in advanced ovarian cancer. This new information may expand treatment choice for such patients.Keywords
This publication has 63 references indexed in Scilit:
- 18F-FDG PET/CT evaluation of patients with ovarian carcinomaNuclear Medicine Communications, 2008
- Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histologyNuclear Medicine Communications, 2007
- In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET — influence of menstrual cycle and endogenous estrogen levelNuclear Medicine and Biology, 2007
- FDG-PET for management of cervical and ovarian cancerGynecologic Oncology, 2005
- Expression of GLUT‐1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F‐18]‐fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovaryInternational Journal of Cancer, 2004
- Ovarian and extraovarian endometriosis-associated cancerObstetrics & Gynecology, 2002
- Positron Emission Tomography/Computed Tomography Imaging for the Detection of Recurrent Ovarian and Fallopian Tube Carcinoma: A Retrospective ReviewGynecologic Oncology, 2002
- Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epitheliaCancer, 2002
- Preoperative Diagnosis of Ovarian Tumors with MR ImagingAmerican Journal of Roentgenology, 2001
- Ki67 Antigen Immunostaining (MIB 1 Monoclonal Antibody) in Serous Ovarian Tumors: Index of Proliferative Activity with Prognostic SignificanceGynecologic Oncology, 1995